Microglia, the parenchymal immune cells of the central nervous system, orchestrate neuroinflammation in response to infection or damage, and promote tissue repair. However, aberrant microglial responses are integral to neurodegenerative diseases and critically contribute to disease progression. Thus, it is important to elucidate how microglia -mediated neuroinflammation is regulated by endogenous factors. Here, we explored the effect of Nerve Growth Factor (NGF), an abundant neurotrophin, on microglial inflammatory responses. NGF, via its high affinity receptor TrkA, downregulated LPS -induced production of pro-inflammatory cytokines and NO in primary mouse microglia and inhibited TLR4 -mediated activation of the NF-κB and JNK pathways. Furthermore, NGF attenuated the LPS -enhanced glycolytic activity in microglia, as suggested by reduced glucose uptake and decreased expression of the glycolytic enzymes Pfkβ3 and Ldhα. Consistently, 2DG -mediated glycolysis inhibition strongly downregulated LPS -induced cytokine production in microglial cells. Our findings demonstrate that NGF attenuates pro-inflammatory responses in microglia and may thereby contribute to regulation of microglia -mediated neuroinflammation.
Introduction
Neuroinflammation is a feature of several Central Nervous System (CNS) diseases, such as Multiple Sclerosis (MS), Alzheimer's Disease (AD), Parkinson's Disease (PD) and Amyotrophic Lateral Sclerosis (ALS) [13, 24] . Microglia, the resident immune cells of the CNS have a central role in neuroinflammation [16, 17] . In homeostasis, microglia coordinate neuronal development and plasticity [16] . They constantly patrol their microenvironment, provide trophic support to surrounding cells and orchestrate synapse formation (synaptic pruning) [16, 17] . In response to tissue damage or infection, microglia get activated and release pro-inflammatory cytokines, reactive oxygen species (ROS) and nitric oxide (NO) [27] . On the other hand, they also promote resolution of inflammation, tissue repair and remodeling through debris clearance by phagocytosis and neurotrophic support [17, 27] . However, aberrant microglial responses are a pathophysiological hallmark of many neurodegenerative diseases, since excessive microglial activation and associated overproduction of pro-inflammatory mediators can cause a neurotoxic environment, which critically contributes to disease progression [28, 6] . Therefore, it is fundamental to gain a better understanding of the regulation of microglia -mediated neuroinflammation [17, 28] .
Nerve Growth Factor (NGF) is an abundant neurotrophin, which is essential for neural development and survival [4] . It is predominantly produced by neurons and astrocytes, but also oligodendrocytes, endothelial cells and microglia [25, 3, 33, 5, 8, 9] . NGF binds with high affinity to the Tropomyosin receptor kinase A (TrkA), a receptor with tyrosine kinase activity, and with lower affinity to the pan-neurotrophin p75 NTR [4] . Here, we investigate the effects of NGF on microglial inflammatory responses. We previously showed that microglia express TrkA, which can be activated by the neurosteroid dehydroepiandrosterone (DHEA), triggering anti-inflammatory responses [1] . Here we show that the prototype ligand of TrkA, NGF, also negatively regulates lipopolysaccharide (LPS) -induced inflammation in a TrkAdependent manner. This anti-inflammatory effect of NGF in microglia is associated with metabolic alterations, as shown by reduced glucose uptake and expression of glycolytic enzymes. These data indicate that NGF is an endogenous homeostatic factor modulating microglia -mediated neuroinflammation.
Materials and methods

Primary microglial culture and treatments
Primary microglial cells were isolated from brains of adult C57BL/6 mice as previously described [1] . Cells were cultured in DMEM/F12 with Glutamax, supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin (all from Invitrogen, Darmstadt, Germany) and 5 ng/ml of murine recombinant Granulocyte and Macrophage Colony Stimulating Factor (GM-CSF) (Peprotech, United States of America, USA) in poly-L-lysine (Sigma-Aldrich, USA)-coated flasks at 37°C and 5% CO 2 . Before treatments, microglial cells were cultured for 2 days in the aforementioned medium without GM-CSF. Thereafter, cells were treated for 24 h with 100 ng/ml NGF (Merck Millipore, Darmstadt, Germany) or vehicle control (PBS) and then incubated again with NGF or PBS together with either 100 ng/ml LPS (Ultrapure LPS, E. coli K12, Invivogen, USA) alone or 100 ng/ml LPS and 20 ng/ml murine Interferon gamma (IFNγ) (Peprotech, USA), as described in the figure legends. In some experiments, microglial cells were pre-treated for 30 min with 1 μM TrkA inhibitor, which inhibits the kinase activity of TrkA (Merck Millipore, Darmstadt, Germany), or control solution containing the same dilution of DMSO. For glycolysis inhibition, microglia were incubated in medium without or with 5 mM 2-deoxy-D-glucose (2DG) (Sigma-Aldrich, USA) for 30 min. All treatments were performed in reduced-serum (1% FBS) DMEM/F12 supplemented with Glutamax and antibiotics.
Bone marrow -derived macrophage (BMDM) culture and treatments
BMDM were prepared from C57BL/6 mice, as previously described [7] . After flushing the bone marrow and lysis of erythrocytes using red blood cell lysis buffer (eBioscience), bone marrow cells were cultured in RPMI-1640 supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin and 10 ng/ml GM-CSF for 7 days. Thereafter, differentiated BMDM were treated for 24 h with 100 ng/ml NGF or PBS, and then incubated again with NGF or PBS together with either 100 ng/ml LPS alone or 100 ng/ml LPS and 20 ng/ml IFNγ. All treatments were performed in reduced -serum (1% FBS) RPMI-1640 supplemented with antibiotics.
Cytokine measurements
Primary microglial cells were plated at a density 0.5 × 10 6 cells/ well in 24-well cell culture plates coated with poly-L-lysine and treated with NGF or vehicle control (PBS) as well as with LPS or vehicle control (PBS). Cytokines were then measured in cell culture supernatants using the Meso Scale Discovery (MSD) V-Plex Pro-inflammatory Mouse Panel (Meso Scale Diagnostics, Rockville, Maryland, USA) in a MSD plate reader (QuickPlex SQ 120, Meso Scale Diagnostics, Rockville, Maryland, USA) according to the manufacturer's protocol. Secretion of TNF was measured using the mouse TNF-alpha DuoSet ELISA kit (R&D Systems, Germany) in a Biotek Synergy HT multi-detection microplate reader (Biotek, Germany) following manufacturer's instructions.
NO measurement
Nitrite and nitrate production was measured in cell lysates using the NO Assay Kit (Fluorometric) (Abcam, Cambridge, United Kingdom) according to manufacturer's instructions. Briefly, primary microglial cells were plated at a density of 1 × 10 6 cells/well in 12-well cell culture plates pre-coated with poly-L-lysine and were incubated with NGF or PBS and then with LPS or PBS, as described in the respective figure legend. Cells were lysed in 200 µl Assay Buffer and total nitrite and nitrate concentration was measured in 2-fold diluted samples following manufacturer's instructions using a Biotek Synergy HT multi-detection microplate reader (Biotek, Germany).
2-Deoxy-D-glucose (2DG) uptake assay
To measure glucose uptake, the Glucose Uptake-Glo Assay (Promega, Mannheim, Germany) was used. Primary mouse microglial cells were plated at a density of 8 × 10 4 cells/well in 96-well cell culture poly-L-lysine-coated plates. Cells were treated or not for 18 h with NGF or vehicle control (PBS) in the presence of LPS or vehicle control (PBS), as described in the figure legend. Cells were washed twice with glucose-free Agilent Seahorse XF Base Medium (102353-100, Agilent, USA) supplemented with 1 mM L-glutamine (Invitrogen, Darmstadt, Germany), pH 7.4 and incubated in the same medium for 45 min at 37°C. 2DG was added to the medium at a final concentration of 10 mM and cells were incubated for 10 min at 37°C. 2DG uptake was measured following the manufacturer's instructions and the luminescence signal was measured using a Biotek Synergy HT multi-detection microplate reader (Biotek, Germany).
BV2 culture and treatments for Western Blot analysis
The murine brain -derived microglial cell line BV2 (ICLC ATL03001) was purchased from Interlab Cell Line Collection (ICLC, Genova, Italy). Cells were maintained in RPMI medium (InVitrogen, Darmstadt, Germany) supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C and 5% CO 2 . Cells were treated or not for different time intervals with NGF (100 ng/ml), LPS (100 ng/ml) or NGF + LPS (both at 100 ng/ml) in RPMI medium with 1% FBS. Western blot analysis was performed as previously described [1] . Briefly, cells were washed twice with ice -cold PBS, lysed in lysis buffer (10 mM Tris pH 7.4, 1% SDS, 1 mM sodium orthovanadate, 1:400 benzonase (Sigma-Aldrich, Munich, Germany)), supplemented with Mini Protease Inhibitor and Phosphatase Inhibitor Cocktail (Roche, Mannheim, Germany) and cell lysates were denatured by heating at 95°C for 3 min. Protein samples (60 μg) were subjected to SDS-PAGE electrophoresis and transferred onto Hybond nitrocellulose membranes (Amersham Biosciences, Germany). Membranes were blocked for one hour in 5% Bovine Serum Albumin (BSA) (Sigma-Aldrich, USA) or 5% non-fat milk diluted in TBS-T buffer (0.15 M NaCl, 2.7 mM KCl, 24.8 mM Trisbase, 0.1% Tween-20), and immunoblotted overnight at 4°C. Antibodies used were rabbit anti-IkB-a (Cell Signalling, #9242, 1:500), mouse anti-phospho-SAPK/JNK (Thr183/Tyr185) (Cell Signalling, #9255, 1:500), rabbit anti-Vinculin (Cell Signaling #4650, 1:1000) and mouse anti-Actin (Abcam, ab3280, 1:1000). Anti-mouse and anti-rabbit HRP-conjugated secondary antibodies (R&D, Wiesbaden-Nordenstadt, Germany) were used at a dilution of 1:2000. After washes with TBS-T, membranes were developed using SuperSignal West Pico Chemiluminescent Substrate (Life Technologies) or SuperSignal West Fempto Chemiluminescent Substrate (Life Technologies) and the luminescent image analyzer LAS-3000 (Fujifilm, Dusseldorf, Germany). The intensity of the bands was quantified with the Fiji software [29] .
RNA extraction and gene expression analysis
Total RNA was isolated from cells using the NucleoSpin RNA isolation kit (Macherey-Nagel, Duren, Germany). RNA was reverse transcribed with the iScript cDNA Synthesis kit (Biorad, Munich, Germany). cDNA was analysed by qPCR using the SsoFast Eva Green Supermix (Bio-Rad, Munich, Germany), a CFX384 real-time System C1000 Thermal Cycler (Bio-Rad) and the Bio-Rad CFX Manager 3.1 software. The relative amount of the different mRNAs was quantified with the ΔΔCt method and using 18S rRNA for normalization [1, 7] . Primers used are described in Table 1 .
Statistical analysis
All values are presented as the mean ± standard errors of the means (SEM). Comparison between groups was made with Mann-Whitney U test, unpaired Student's t-test or one-way ANOVA with p ≤ 0.05 as a significance level using GraphPad Prism 6.0 Software (GraphPad Software, CA, USA).
Results
NGF attenuated pro-inflammatory responses of microglial cells in a TrkA -dependent manner
We first examined the effect of NGF on microglial inflammatory responses induced by LPS. To this end, mouse primary microglial cells pre-treated with either NGF or vehicle control (PBS) were stimulated with LPS or vehicle control (PBS) and analysed for cytokine production. NGF pre-treatment alone did not influence cytokine release (not shown), while it significantly downregulated LPS -induced tumour necrosis factor (TNF), interleukin (IL)6 and IL1beta release (Fig. 1A-C) and LPS -induced Tnf, Il6 and Il1beta gene expression (Fig. 1D-F) . Furthermore, NO production in LPS -stimulated microglia was significantly reduced by NGF pre-treatment (Fig. 1G) . NGF did not affect cytokine expression or NO production in the absence of LPS (not shown). On the contrary, NGF did not influence cytokine expression in BMDM treated with LPS ( Supplementary Fig. 1A-B) or LPS and IFNγ ( Supplementary Fig. 1C-D) .
Microglia express the NGF receptor TrkA [1, 26] . Hence, we next examined whether the anti-inflammatory effect of NGF was mediated through TrkA. Cells were pre-treated with NGF in the presence of a TrkA inhibitor or vehicle control and were subsequently activated with LPS. Inhibition of TrkA abolished the inhibitory effect of NGF on LPSstimulated Il6 expression in microglia cells (Fig. 1H) . The anti-inflammatory effect of NGF was also observed in microglia activated with LPS and IFNγ. NGF pre-treatment down-regulated Tnf and Il6 expression in cells stimulated with LPS and IFNγ and these inhibitory effects of NGF were reversed by TrkA inhibition (Fig. 1I,J) . Our findings collectively indicate that NGF, acting through TrkA, reduced inflammatory reactions of microglial cells.
NGF down-regulated TLR4 signalling in microglial cells
Next, we questioned how NGF mediates its anti-inflammatory effects in LPS -stimulated microglial cells. LPS activates through Toll-like receptor 4 (TLR4) nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), as evidenced by inhibitor of κB alpha (IκBα) degradation, and JUN N-terminal Kinase (JNK), which both mediate pro-inflammatory effects in microglia [20] . BV2 cells were treated with NGF and LPS for different time intervals and the activation of these two pathways was examined. LPS-induced degradation of IκBα was reversed by co-incubation with NGF ( Fig. 2A) . Similarly, NGF also inhibited LPS -induced JNK phosphorylation (Fig. 2B) . These data suggest that NGF regulated early TLR4 signalling in microglia thereby limiting microglial inflammatory activation.
NGF reduced LPS -driven glycolytic reprogramming in microglia
Previous reports demonstrated that LPS stimulation of microglia leads to increased glycolysis [12, 21] . We questioned whether inhibition of glycolysis affects pro-inflammatory activation of microglia. To this end, mouse primary microglial cells were stimulated with LPS in the presence of the non-metabolisable glucose analogue 2DG for restriction of glycolysis or control solution and analysed for pro-inflammatory gene expression. 2DG significantly reduced LPS -induced release of IL6 and IL1β (Fig. 3A,B) , and expression of Il6, Il1β and nitric oxide synthase 2 (Nos2) (Fig. 3D,E,G) , as compared to control treated cells. On the contrary, 2DG did not influence LPS -induced TNF release or Tnf expression (Fig. 3C,F) , suggesting that TNF expression is regulated by LPS independently of glycolysis.
These findings prompted us to investigate whether NGF affects LPSdriven glycolytic activity in microglial cells. First, we addressed the effect of NGF on glucose uptake of LPS -activated microglia. Mouse primary microglial cells were treated for 18 h with LPS in the presence of NGF or vehicle control (PBS) and then glucose uptake was determined using 2DG. NGF significantly reduced LPS -induced 2DG uptake (Fig. 4A) . Since the glycolytic rate is controlled by rate-limiting glycolytic enzymes [31] , we then examined, whether NGF influences the expression of the rate-limiting glycolytic enzymes Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (Pfkfb3) and Lactate dehydrogenase A (Ldhα). Consistently with its inhibitory effect on LPS-induced glucose uptake, NGF downregulated the LPS -enhanced expression of Pfkfb3 (Fig. 4B) and Ldhα (Fig. 4C) . Collectively, these data suggest that NGF exerts anti-inflammatory effects and attenuates inflammation -associated upregulation of glycolysis in LPS -stimulated microglia.
Discussion
Neurodegenerative diseases are characterized by microglia -mediated neuroinflammation [13] . Aberrant microglial activation contributes to neurotoxicity and neuronal destruction and thereby to the pathology of neurodegenerative CNS diseases [17, 24, 27] . Microglial cells are highly sensitive to their microenvironment: they constantly surveil their surrounding with their moving processes seeking for potential insults, while they get rapidly activated by infectious or inflammatory stimuli [17] . Conceivably, similarly to their responsiveness to inflammatory signals, microglial cells could also be sensitive to factors present in their microenvironment conferring regulation of microglial responses.
Neurotrophins constitute a family of growth factors with important roles in neuronal growth, differentiation and survival [4] . NGF is one of the best -studied neurotrophins, which, besides its neuroprotective potential, also exerts immunomodulatory properties [19] . Its receptor TrkA is expressed in a number of peripheral immune cells, such as Band T-lymphocytes, monocytes/macrophages and dendritic cells [19] , as well as microglial cells [1] . Both pro-and anti-inflammatory effects were described for NGF [19] . For instance, it promotes survival of immune cells, activates chemotaxis and phagocytosis in neutrophils and macrophages, induces degranulation of mast cells and promotes differentiation and immune functions of B cells [19] . Thus, with few [10] [11] [12] [13] [14] [15] [16] exceptions, such as its anti-inflammatory effects in monocytes [23] , NGF in the periphery acts in a rather pro-inflammatory fashion. On the contrary, in the CNS, NGF functions are predominantly anti-inflammatory. Intraventricular administration of NGF in Experimental Autoimmune Encephalitis (EAE), a widely used model of MS, reduced inflammatory cell infiltration and demyelination, decreased IFNγ and increased IL10 levels, delayed disease onset and decreased disease severity [11, 2, 32] . In accordance, transfer of myelin basic protein (MBP) -specific CD4 + T cells transduced to overexpress NGF failed to induce EAE, while it efficiently suppressed induction of EAE by nontransduced MBP-specific T cell transfer [11] . Furthermore, NGF depletion was associated with enhanced brain inflammation in rats subjected to EAE [18] . Moreover, NGF -mediated engulfment of Aβ by microglia dampened Aβ -induced microglial inflammation in a TrkA - dependent manner and conferred neuronal protection against Aβ-induced loss of dendritic spines [26, 34] .
Here we studied the effect of NGF on LPS -induced microglial inflammatory responses. In accordance to its reported anti-inflammatory role in Αβ -stimulated microglia [26] , NGF attenuated TLR4 -mediated pro-inflammatory activation. This effect was mediated through TrkA and was likewise observed in microglia activated with both LPS and IFNγ. Interestingly, NGF inhibited early TLR4 -mediated activation of the NFκB and JNK pathways, suggesting that TrkA signalling interferes with TLR4 signalling in microglia. However, the exact mechanism of this interference remains to be discovered in a future study.
Moreover, NGF attenuated the LPS -induced glycolytic shift in microglia. In macrophages, the counterparts of microglia in the periphery, inflammation is associated with increased glycolysis, in order to cover the enhanced energy demands of inflammatory cells [15] . Similarly, microglial inflammatory activation is also linked to enhanced glycolysis [12, 14, 21] . Here we showed that restriction of glycolysis by 2DG downregulated the LPS -induced expression of Il6, Il1β and Nos2 in microglia. In contrast, LPS -induced Tnf expression was not influenced by 2DG -mediated inhibition of glycolysis, similarly to what was reported in macrophages [30] . These observations collectively indicate that glycolysis critically facilitates microglial inflammation and that NGF attenuates the latter at least partially through modulation of glycolysis.
Thus, NGF emerges as a factor of therapeutic interest in the context of neurodegenerative diseases, not only due to its neuroprotective role, but also due to its role in regulation of neuroinflammation. However, therapeutic NGF administration is limited by its inability to cross the Blood Brain Barrier (BBB) and its poor pharmacokinetic properties [10] . Therefore, systemic administration of small BBB permeable molecules targeting TrkA appears as an attractive perspective. In this context, we have recently shown that systemically administered DHEA, as well as a non-metabolisable analogue of it, negatively regulated microglial -mediated neuroinflammation through TrkA activation Fig. 2 . NGF downregulated TLR4 signalling in microglia. (A) BV2 cells were treated or not for 60 min with vehicle control (PBS), 100 ng/ml LPS and PBS, 100 ng/ml NGF or the combination of LPS and NGF (both 100 ng/ml) and lysates were analysed by western blot for IκB. Actin was used as loading control. Representative blots from one out of five independent experiments are shown. (B) BV2 cells were treated with 100 ng/ml NGF, 100 ng/ml LPS and PBS, or NGF and LPS (each at 100 ng/ ml) for the indicated time intervals and lysates were analysed by western blot for phosphoJNK. Vinculin was used as loading control. The intensity of phosphoJNK and Vinculin bands was quantified at 30 min in 4 independent experiments and in each experiment the ratio phosphoJNK1(46 kDa) / Vinculin and phosphoJNK2(54 kDa) / Vinculin was set as 1 for samples treated with PBS+LPS. Data are mean ± SEM (n = 4); * P ≤ 0.05. [1, 22] . The present study together with our previous study therefore clearly establish the anti-inflammatory role of TrkA in microglia. Thus, modulation of TrkA signalling might represent an interesting way to therapeutically interfere with microglia -mediated neuroinflammation.
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